CA3111447A1 - Methods of treating mycobacterial infections using tetracycline compounds - Google Patents

Methods of treating mycobacterial infections using tetracycline compounds Download PDF

Info

Publication number
CA3111447A1
CA3111447A1 CA3111447A CA3111447A CA3111447A1 CA 3111447 A1 CA3111447 A1 CA 3111447A1 CA 3111447 A CA3111447 A CA 3111447A CA 3111447 A CA3111447 A CA 3111447A CA 3111447 A1 CA3111447 A1 CA 3111447A1
Authority
CA
Canada
Prior art keywords
alkyl
subject
alkynyl
alkenyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3111447A
Other languages
English (en)
French (fr)
Inventor
Michael Henry Cynamon
Michael P. Draper
Judith N. Steenbergen
S. Ken Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paratek Pharmaceuticals Inc
US Department of Veterans Affairs
Original Assignee
Paratek Pharmaceuticals Inc
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals Inc, US Department of Veterans Affairs filed Critical Paratek Pharmaceuticals Inc
Publication of CA3111447A1 publication Critical patent/CA3111447A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3111447A 2018-09-04 2019-09-03 Methods of treating mycobacterial infections using tetracycline compounds Pending CA3111447A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862726738P 2018-09-04 2018-09-04
US62/726,738 2018-09-04
US201862731410P 2018-09-14 2018-09-14
US62/731,410 2018-09-14
US201862746039P 2018-10-16 2018-10-16
US62/746,039 2018-10-16
US201862760131P 2018-11-13 2018-11-13
US62/760,131 2018-11-13
PCT/US2019/049368 WO2020051151A1 (en) 2018-09-04 2019-09-03 Methods of treating mycobacterial infections using tetracycline compounds

Publications (1)

Publication Number Publication Date
CA3111447A1 true CA3111447A1 (en) 2020-03-12

Family

ID=69722600

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3111447A Pending CA3111447A1 (en) 2018-09-04 2019-09-03 Methods of treating mycobacterial infections using tetracycline compounds

Country Status (13)

Country Link
US (2) US12161655B2 (https=)
EP (1) EP3846805A4 (https=)
JP (2) JP7466544B2 (https=)
KR (2) KR20260036400A (https=)
CN (1) CN113164456A (https=)
AU (2) AU2019335203B2 (https=)
BR (1) BR112021004057A2 (https=)
CA (1) CA3111447A1 (https=)
MA (1) MA53564A (https=)
MX (2) MX2021002503A (https=)
PH (1) PH12021550452A1 (https=)
SG (1) SG11202102149SA (https=)
WO (1) WO2020051151A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7840880B2 (ja) * 2020-06-11 2026-04-06 パラテック ファーマシューティカルズ，インコーポレイテッド オマダサイクリンの結晶形態、その合成方法及びその使用方法
TW202237116A (zh) * 2020-12-02 2022-10-01 日商塩野義製藥股份有限公司 以組合細胞色素bc1抑制劑與克拉黴素或阿奇黴素為特徵之用於治療分枝桿菌感染之藥物
JP2024511419A (ja) * 2021-03-24 2024-03-13 インスメッド インコーポレイテッド 非結核性抗酸菌肺疾患を治療するための併用療法
WO2025221846A1 (en) * 2024-04-18 2025-10-23 St. Jude Children's Research Hospital, Inc. Compositions and methods for treating non-tuberculosis mycobacteria infections

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009175B1 (ru) 2000-07-07 2007-12-28 Трастис Оф Тафтс Коллидж Замещенные соединения миноциклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния млекопитающего
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2311451A1 (en) 2002-03-08 2011-04-20 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
PT2271348T (pt) * 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
TWI680117B (zh) 2008-05-19 2019-12-21 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
KR101732084B1 (ko) 2011-07-26 2017-05-02 케이비피 바이오사이언시즈 씨오., 엘티디. 9-아미노메틸 치환된 테트라사이클린 화합물
JP2015527403A (ja) 2012-09-11 2015-09-17 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖプロテアーゼ阻害剤
CA3018872A1 (en) * 2016-03-24 2017-09-28 Paratek Pharmaceuticals, Inc. Methods of treating a bacterial infection in a subject at risk of developing c. difficile infection
JP2019514952A (ja) * 2016-05-02 2019-06-06 パラテック ファーマシューティカルズ，インコーポレイテッド ９−アミノメチルミノサイクリン化合物及び尿路感染症（ｕｔｉ）の処置におけるその使用方法
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途
GB201615693D0 (en) * 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations

Also Published As

Publication number Publication date
JP2021536504A (ja) 2021-12-27
US20210346408A1 (en) 2021-11-11
EP3846805A1 (en) 2021-07-14
CN113164456A (zh) 2021-07-23
US20250332178A1 (en) 2025-10-30
US12161655B2 (en) 2024-12-10
MX2021002503A (es) 2021-06-15
AU2025234215A1 (en) 2025-10-16
KR20260036400A (ko) 2026-03-16
AU2019335203B2 (en) 2025-06-19
KR102933150B1 (ko) 2026-03-03
BR112021004057A2 (pt) 2021-05-25
EP3846805A4 (en) 2022-08-24
MA53564A (fr) 2021-07-14
WO2020051151A1 (en) 2020-03-12
SG11202102149SA (en) 2021-04-29
PH12021550452A1 (en) 2021-12-06
MX2024008671A (es) 2024-07-23
JP2024084794A (ja) 2024-06-25
KR20210090160A (ko) 2021-07-19
AU2019335203A1 (en) 2021-05-06
JP7466544B2 (ja) 2024-04-12

Similar Documents

Publication Publication Date Title
US20250332178A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
CA2842777C (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
TWI419690B (zh) 使用化合物ｉ來預防或治療生物膜的形成
KR20260022303A (ko) 항박테리아제들을 포함하는 약학적 조합 및 이의 조성물
JP2002500189A (ja) 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
KR101850265B1 (ko) 항균제 및 타조박탐을 포함하는 조성물
JP5276653B2 (ja) カルバペネム類を含む殺菌性抗ｍｒｓａ活性医薬組成物
RU2831120C2 (ru) Способы лечения микобактериальных инфекций с применением тетрациклиновых соединений
US20060073156A1 (en) Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract
US20230364065A1 (en) Antibiotic combination therapies
CN114617886A (zh) 化合物及其药学上可接受的盐的抗菌用途
Espinoza-Gonzalez et al. Evaluation of the combined therapy of DA-7218, a new oxazolidinone, and trimethoprim/sulfamethoxazole in the treatment of experimental actinomycetoma by Nocardia brasiliensis
Session I92-MAY 1978 o
HK1146223A (en) Triazol compounds for treating biofilm formation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240812

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240830

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240830

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240830

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250123

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250408

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250408

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250829

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250829

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250923

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260122

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260129

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260129

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260129